tetano
Editor, Senior Moderator
Biodes Manuf
. 2021 Feb 3;1-16.
doi: 10.1007/s42242-020-00114-3. Online ahead of print.
Peptides-based vaccine against SARS- n CoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection
Zainularifeen Abduljaleel[SUP] 1 2 3 [/SUP], Faisal A Al-Allaf[SUP] 1 [/SUP], Syed A Aziz[SUP] 4 [/SUP]
Affiliations
Abstract
The World Health Organization has declared the rapidly spreading coronavirus to be a global pandemic. The FDA is yet to approve a vaccine for human novel coronavirus. Here, we developed a peptide-based vaccine and used high-throughput screening by molecular dynamics simulation to identify T-cell- and β-cell-recognized epitopes for producing specific antibodies against SARS-nCoV-2. We construct ~ 12 P' antigenic epitope peptides to develop a more effective vaccine and identify specific antibodies. These epitope peptides selectively presented the best antigen presentation scores for both human pMHC class I and II alleles to develop a strong binding affinity. All antigens identified of SARS-nCoV-2 different proteins by each attached specific ~ 1-7 L linker adaptor were used to construct a broad single peripheral peptide vaccine. It is expected to be highly antigenic with a minimum allergic effect. As a result of these exciting outcomes, expressing a vaccine using the intimated peptide was highly promising and positive to be highly proposed as epitope-based peptide vaccine of specific antibody against SARS-nCoV-2 by initiating T cells and β-cells. An in vitro study for the proposed peptide-based vaccine is mostly recommended. Further clinical trials are required to check the efficacy of this vaccine.
Keywords: COVID-19; Cell-penetrating peptides; Lipid membrane; Peptide-based vaccine; SARS-nCoV-2; Vaccine efficacy.
. 2021 Feb 3;1-16.
doi: 10.1007/s42242-020-00114-3. Online ahead of print.
Peptides-based vaccine against SARS- n CoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection
Zainularifeen Abduljaleel[SUP] 1 2 3 [/SUP], Faisal A Al-Allaf[SUP] 1 [/SUP], Syed A Aziz[SUP] 4 [/SUP]
Affiliations
- PMID: 33552630
- PMCID: PMC7856345
- DOI: 10.1007/s42242-020-00114-3
Abstract
The World Health Organization has declared the rapidly spreading coronavirus to be a global pandemic. The FDA is yet to approve a vaccine for human novel coronavirus. Here, we developed a peptide-based vaccine and used high-throughput screening by molecular dynamics simulation to identify T-cell- and β-cell-recognized epitopes for producing specific antibodies against SARS-nCoV-2. We construct ~ 12 P' antigenic epitope peptides to develop a more effective vaccine and identify specific antibodies. These epitope peptides selectively presented the best antigen presentation scores for both human pMHC class I and II alleles to develop a strong binding affinity. All antigens identified of SARS-nCoV-2 different proteins by each attached specific ~ 1-7 L linker adaptor were used to construct a broad single peripheral peptide vaccine. It is expected to be highly antigenic with a minimum allergic effect. As a result of these exciting outcomes, expressing a vaccine using the intimated peptide was highly promising and positive to be highly proposed as epitope-based peptide vaccine of specific antibody against SARS-nCoV-2 by initiating T cells and β-cells. An in vitro study for the proposed peptide-based vaccine is mostly recommended. Further clinical trials are required to check the efficacy of this vaccine.
Keywords: COVID-19; Cell-penetrating peptides; Lipid membrane; Peptide-based vaccine; SARS-nCoV-2; Vaccine efficacy.